Related Experiment Video
Updated: Jul 10, 2026
10:33
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
Published on: July 23, 2016
10.4K
Exosomal Drug Delivery Systems: A Novel Therapy Targeting PD-1 in Septic-ALI
Yuanlan Huang1, Gang Li1, Zeqi Chen1
1Department of Blood Transfusion, Naval Specialty Medical Center, Naval Medical University, Shanghai, 200050, People's Republic of China.
Stem Cell Reviews and Reports
|September 5, 2024
Summary
Human umbilical cord mesenchymal stem cell-derived exosomes (HucMSCs-EXOs) loaded with anti-programmed cell death 1 (PD-1) peptide, named MEP, effectively treat septic-induced acute lung injury (ALI). MEP outperforms individual components in reducing inflammation and improving lung injury in mice.
Area of Science:
- Biomedical Engineering
- Immunology
- Regenerative Medicine
Background:
- Sepsis-induced cytokine storm can cause acute lung injury (ALI).
- Human umbilical cord mesenchymal stem cell-derived exosomes (HucMSCs-EXOs) exhibit immunosuppressive and anti-inflammatory properties.
- Programmed cell death receptor 1 (PD-1) is vital for immune homeostasis.
Purpose of the Study:
- To investigate the synergistic therapeutic effect of exosomes loaded with anti-PD-1 peptide (MEP) on septic-ALI.
- To elucidate the therapeutic mechanism of MEP in treating septic-ALI.
Main Methods:
- Engineering HucMSCs-EXOs to create MEP by loading anti-PD-1 peptide.
- Evaluating MEP's therapeutic effect in vivo (septic-ALI mice) and in vitro.
- Analyzing inflammatory markers, cytokine levels, cell apoptosis, macrophage polarization, and gene expression.
Main Results:
- MEP significantly improved lung injury index in septic-ALI mice compared to individual components.
- MEP reduced inflammatory markers (CRP, PCT) and pro-inflammatory cytokines (TNF-α, IL-1β).
- MEP increased anti-inflammatory cytokine (IL-10), CD68+ macrophages, promoted M2 macrophage polarization, and decreased inflammasome-related genes.
Conclusions:
- MEP demonstrates superior therapeutic efficacy for septic-ALI compared to anti-PD-1 peptide or EXOs alone.
- MEP effectively modulates immune responses and reduces inflammation in septic-ALI.
- MEP shows promise as a novel therapeutic agent for treating septic-ALI.
Related Concept Videos
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...